BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Soriano V, Labarga P, Fernandez-montero JV, Mendoza CD, Benítez-gutiérrez L, Peña JM, Barreiro P. Drug interactions in HIV-infected patients treated for hepatitis C. Expert Opinion on Drug Metabolism & Toxicology 2017;13:807-16. [DOI: 10.1080/17425255.2017.1351942] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Chen L, Du L, Kang S, Ma F, Li C, He M, Bai L, Tang H. Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China. Sci Rep 2021;11:11301. [PMID: 34050222 DOI: 10.1038/s41598-021-90706-5] [Reference Citation Analysis]
2 Lledó G, Benítez-Gutiérrez L, Arias A, Requena S, Cuervas-Mons V, de Mendoza C. Benefits of hepatitis C cure with antivirals: why test and treat? Future Microbiol 2019;14:425-35. [PMID: 30900911 DOI: 10.2217/fmb-2019-0041] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Dogra A, Bhatt S, Magotra A, Sharma A, Kotwal P, Gour A, Wazir P, Singh G, Nandi U. Intervention of curcumin on oral pharmacokinetics of daclatasvir in rat: A possible risk for long-term use. Phytother Res 2018;32:1967-74. [PMID: 29806225 DOI: 10.1002/ptr.6123] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
4 Aghemo A, Piroth L, Bhagani S. What do clinicians need to watch for with direct-acting antiviral therapy? J Int AIDS Soc 2018;21 Suppl 2:e25076. [PMID: 29633552 DOI: 10.1002/jia2.25076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
5 Néant N, Solas C. Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection. Int J Antimicrob Agents 2020;56:105571. [PMID: 30394302 DOI: 10.1016/j.ijantimicag.2018.10.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 Bischoff J, Mauss S, Cordes C, Lutz T, Scholten S, Moll A, Jäger H, Cornberg M, Manns MP, Baumgarten A, Rockstroh JK. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? HIV Med 2018;19:299-307. [PMID: 29368456 DOI: 10.1111/hiv.12579] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
7 von Felden J, Vermehren J, Ingiliz P, Mauss S, Lutz T, Simon KG, Busch HW, Baumgarten A, Schewe K, Hueppe D, Boesecke C, Rockstroh JK, Daeumer M, Luebke N, Timm J, Schulze Zur Wiesch J, Sarrazin C, Christensen S. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection. Aliment Pharmacol Ther. 2018;47:1288-1295. [PMID: 29536554 DOI: 10.1111/apt.14592] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 9.3] [Reference Citation Analysis]
8 Boff da Costa R, Boff Costa M, Longo L, Miotto DE, Hirata Dellavia G, Trucollo Michalczuk M, Reis Álvares-da-Silva M. Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications. PLoS One 2021;16:e0245767. [PMID: 33577593 DOI: 10.1371/journal.pone.0245767] [Reference Citation Analysis]
9 Isakov V, Gankina N, Morozov V, Kersey K, Lu S, Osinusi A, Svarovskaia E, Brainard DM, Salupere R, Orlova-Morozova E, Zhdanov K. Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection. Clin Drug Investig 2018;38:239-47. [PMID: 29177645 DOI: 10.1007/s40261-017-0606-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
10 Gao LH, Nie QH, Zhao XT. Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C. Int J Gen Med 2021;14:289-301. [PMID: 33536776 DOI: 10.2147/IJGM.S283910] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Xiao H, Chen J, Wang J, Li J, Yang F, Lu H. Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection. Medicine (Baltimore) 2019;98:e16524. [PMID: 31348267 DOI: 10.1097/MD.0000000000016524] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wilson E, Covert E, Hoffmann J, Comstock E, Emmanuel B, Tang L, Husson J, Chua J, Price A, Mathur P, Rosenthal E, Kattakuzhy S, Masur H, Kottilil S. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY). J Hepatol. 2019;71:498-504. [PMID: 31173815 DOI: 10.1016/j.jhep.2019.05.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
13 Librelotto CS, Souza AP, Álvares-DA-Silva MR, Simon D, Dihl RR. Evaluation of the genetic toxicity of sofosbuvir and simeprevir with and without ribavirin in a human-derived liver cell line. An Acad Bras Cienc 2021;93:e20200632. [PMID: 34586319 DOI: 10.1590/0001-3765202120200632] [Reference Citation Analysis]
14 Abdelaziz H, Omar H, Khalil M, Cordie A, Mohamed R, AbdAllah M, Abdel Maksoud MH, El Garhy N, Ali L, El Serafy M, Esmat G, Doss W. Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience. Expert Rev Anti Infect Ther 2021;:1-7. [PMID: 34751609 DOI: 10.1080/14787210.2022.2004117] [Reference Citation Analysis]